BlyS is up-regulated by hypoxia and promotes migration of human breast cancer cells

Journal of Experimental & Clinical Cancer Research

Shengtao Yuan²  Luyong Zhang¹  Wenting Shi¹  Jin Liu¹  Liang Chen¹  Dongdong Fang²  Liqiang Zhou²  Renping Zhao¹  Sensen Lin²  Li Sun¹  Jing Zhu² 

[1] Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing 210009, Peoples Republic of China;National Nanjing New Drug Screening Center, China Pharmaceutical University, Nanjing 210009, Peoples Republic of China

关键词: Cell migration;    BLyS;    Hypoxia;   

Others  :  826667
DOI  :  10.1186/1756-9966-31-31

 received in 2012-01-06, accepted in 2012-03-31,  发布年份 2012

【 摘 要 】

Background

The role of B Lymphocyte Stimulator (BLyS) in the survival of malignant B cells and the maintenance of normal B cell development and homeostasis has been intensively studied in the literature. However, the influence of BLyS on breast cancer progression remains unclear. The study aimed to investigate the effect of hypoxia on BLyS regulation, cell migratory response to BLyS and the possible molecular mechanisms.

Methods

In this study, we examined the role of BLyS in the migration of human breast cancer cells by transwell assay. We also explored whether BLyS and its receptors expressed in human breast cancer cell lines by immunofluorescence and Western Blotting. Then we detected the expression level of BLyS in both normoxic and hypoxic conditions by real time-PCR and Western Blotting. Pathways involved were confirmed by Western Blotting, immunofluorescence, transwell assay and luciferase assay.

Results

According to our study, the expression level of BlyS was increased in human breast cancer cell lines in hypoxic conditions. Up-regulation of this protein led to activation and nuclear translocation of NF-kappa B p65. We also found that the number of migrated cells was increased in the presence of BLyS and inhibition of phosphorylation of Akt attenuated the enhanced migratory response.

Conclusions

It suggested that better understanding of BLyS, an immunopotentiator, may offer a potential therapeutic target for the treatment of human breast cancers. In addition, BLyS promoted breast cancer cells migration, underscoring the necessity of appropriate applications of immunopotentiators to cancer treatment.

【 授权许可】

   
2012 Zhu et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Woodland RT, Schmidt MR, Thompson CB: BLyS and B cell homeostasis. Semin Immunol 2006, 18:318-326.
• [2]Tangye SG, Bryant VL, Cuss AK, Good KL: BAFF, APRIL and human B cell disorders. Semin Immunol 2006, 18:305-317.
• [3]Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel K, Gross JA, Greipp PR, Jelinek DF: Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004, 103:689-694.
• [4]Parameswaran R, David HB, Sharabi A, Zinger H, Mozes E: B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus. Clin Immunol 2009, 131:223-232.
• [5]Kalled SL: Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol 2006, 18:290-296.
• [6]Pelekanou V, Kampa M, Kafousi M, Darivianaki K, Sanidas E, Tsiftsis DD, Stathopoulos EN, Tsapis A, Castanas E: Expression of TNF-superfamily members BAFF and APRIL in breast cancer: immunohistochemical study in 52 invasive ductal breast carcinomas. BMC Cancer 2008, 8:76. BioMed Central Full Text
• [7]Rosmorduc O, Housset C: Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010, 30:258-270.
• [8]Jeong HJ, Chung HS, Lee BR, Kim SJ, Yoo SJ, Hong SH, Kim HM: Expression of proinflammatory cytokines via HIF-1alpha and NF-kappa B activation on desferrioxamine-stimulated HMC-1 cells. Biochem Biophys Res Commun 2003, 306:805-811.
• [9]Yan M, He D, Zhang P, Zhou XJ, Chen WT: Inflammatory factors promote oral squamous cell carcinoma cells metastasis, via nuclear factor kappa B signal pathway in vitro. Zhonghua Kou Qiang Yi Xue Za Zhi 2010, 45:146-151.
• [10]Huang G, Yang Y, Xu Z, Zhou P, Gong W, Li Y, Fan J, He F: Downregulation of B lymphocyte stimulator expression by curcumin in B lymphocyte via suppressing nuclear translocation of NF-kappa B. Eur J Pharmacol 2011, 650:451-457.
• [11]Pascal S, Fabienne M, Veronique S, Kay H, Jean LB, Nils H, Christine A, Pornsri L, Sarah B, Hans AO, Danila V, Pedro R, Christiane WF, Rudolph HZ, Jeffrey LB, Jurg T: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999, 189:1747-1758.
• [12]Geertruida MK, Berengere PB, Michael H, Jan PM: TWE-PRIL: a fusion protein of TWEAK and APRIL. Biochem Pharmacol 2003, 66:1427-1432.
• [13]Fu L, Lin-Lee YC, Pham LV, Tamayo AT, Yoshimura LC, Ford RJ: BAFF-R promotes cell proliferation and survival through interaction with IKK-beta and NF-kappa B/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. Blood 2009, 113:4627-4636.
• [14]Salminen A, Huuskonen J, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T: Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging. Ageing Res Rev 2008, 7:83-105.
• [15]Mohamed KM, Le A, Duong H, Wu Y, Zhang Q, Messadi DV: Correlation between VEGF and HIF-1alpha expression in human oral squamous cell carcinoma. Exp Mol Pathol 2004, 76:143-152.
• [16]Villa E, Fattovich G: No inflammation? No cancer! Clear HBV early and live happily. J Hepatol 2010, 52:768-770.
• [17]Lu H, Ouyang WM, Huang CS: Inflammation, a key event in cancer development. Mol Cancer Res 2006, 4:221-233.
• [18]Erez N, Truitt M, Olson P, Arron ST, Hanahan D: Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappa B-Dependent Manner. Cancer Cell 2010, 17:135-147.
• [19]Hinohara K, Gotoh N: Inflammatory signaling pathways in self-renewing breast cancer stem cells. Curr Opin Pharmacol 2010, 10:650-654.
• [20]Lopez-Novoa JM, Nieto MA: Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 2009, 1:303-314.
• [21]Florian RG, Tim FG, Jin MP, Li ZW, Laurence JE, Martin FK, Michael K: IKKβ links inflammation and tumotigensis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296.
• [22]Yu YY, Li Q, Zhu ZG: NF-kappa B as a molecular target in adjuvant therapy of gastrointestinal carcinomas. Eur J Surg Oncol 2005, 31:386-392.
• [23]Pacifico F, Leonardi A: Role of NF-κB in thyroid cancer. Mol Cell Endocrinol 2009, 321:29-35.
• [24]Gonzalez-Perez RR, Xu Y, Guo S, Watters A, Zhou W, Leibovich SJ: Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkappa B/HIF-1alpha activation. Cell Signal 2010, 22:1350-1362.
• [25]Mi J, Zhang X, Liu Y, Reddy SK, Rabbani ZN, Sullenger BA, Clary BM: NF-kappa B inhibition by an adenovirus expressed aptamer sensitizes TNFalpha-induced apoptosis. Biochem Biophys Res Commun 2007, 359:475-480.
• [26]Scherbakov AM, Lobanova YS, Shatskaya VA, Krasil'nikov MA: The breast cancer cells response to chronic hypoxia involves the opposite regulation of NF-kB and estrogen receptor signaling. Steroids 2009, 74:535-542.
• [27]Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, Harder B, Ristow KM, Bram RJ, Jelinek DF, Gross JA, Ansell SM: Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004, 104:2247-2253.
• [28]Ryu CH, Park SA, Kim SM, Lim JY, Jeong CH, Jun JA, Oh JH, Park SH, Oh WI, Jeun SS: Migration of human umbilical cord blood mesenchymal stem cells mediated by stromal cell-derived factor-1/CXCR4 axis via Akt, ERK, and p38 signal transduction pathways. Biochem Biophys Res Commun 2010, 398:105-110.
• [29]Gamell C, Susperregui AG, Bernard O, Rosa JL, Ventura F: The p38/MK2/Hsp25 pathway is required for BMP-2-induced cell migration. PLoS One 2011, 6:e16477.
• [30]Patke A, Mecklenbrauker I, Erdjument-Bromage H, Tempst P, Tarakhovsky A: BAFF controls B cell metabolic fitness through a PKC beta- and Akt-dependent mechanism. J Exp Med 2006, 203:2551-2562.